Ka. Leopold et al., CUMULATIVE MINUTES WITH T(90) GREATER THAN TEMPINDEX IS PREDICTIVE OFRESPONSE OF SUPERFICIAL MALIGNANCIES TO HYPERTHERMIA AND RADIATION, International journal of radiation oncology, biology, physics, 25(5), 1993, pp. 841-847
Purpose: To better define thermal parameters related to tumor response
in superficial malignancies treated with combined hyperthermia and ra
diation therapy.Methods and materials: Patients were randomized to rec
eive one or two hyperthermia treatments per week with hyperthermia giv
en during each week of irradiation. Hyperthermia was given for 60 min
with treatments begun within 1 hr following irradiation. Power was inc
reased to patient tolerance or normal tissue temperature of 43.0-degre
es-C. Irradiation was generally given 5 times per week with doses pres
cribed to normal tissue tolerance (generally 24-70 Gy at 1.8-2.5 Gy pe
r fraction). Multipoint thermometry was used with temperatures obtaine
d every 5 min. Results: One hundred eleven individual treatment fields
containing 1 or more tumor nodules were completely evaluable. The com
plete and overall response rates were 46% and 80%, respectively. Forty
-one percent of all treatment fields (51% of responding lesions) remai
ned controlled at 2 years. Multivariate analysis revealed that the cum
ulative minutes that the temperature achieved by 90% of the measured t
umor sites (T90) was greater-than-or-equal-to 40.0-degrees-C, tumor hi
stology, tumor volume, and radiation dose were significantly associate
d with complete tumor response. The complete response rate was not sig
nificantly affected by the number of hyperthermia treatments given per
week. The incidence of clinically significant complications was low.
Conclusions: These results support the usefulness of the cumulative mi
nute system in describing time-temperature relationships. The signific
ance of thermal variables with regard to tumor response strongly suppo
rts the contention that hyperthermia can be a useful adjunct to irradi
ation for the local control of cancer.